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OBJECTIVES We sought to investigate the impact of adjunct sildenafil on exercise capacity and
hemodynamic parameters in patients with pulmonary arterial hypertension (PAH) who
fulfilled predefined criteria of deterioration despite ongoing treatment with inhaled iloprost.
BACKGROUND Inhaled iloprost is an effective therapy in PAH. The phosphodiesterase-5 inhibitor sildenafil
exerts pulmonary vasodilation and may amplify prostanoid efficacy.
METHODS Of 73 PAH patients receiving long-term inhaled iloprost treatment, 14 fulfilled criteria of
deterioration unresponsive to conventional treatment. These patients received adjunct oral
sildenafil over a period of nine to 12 months, leaving the inhalative iloprost regimen
unchanged.
RESULTS Before iloprost therapy, the baseline 6-min walking distance was 217  31 m (mean 
SEM), with an improvement to 305  28 m within the first three months of iloprost
treatment and a subsequent decline to 256 30 m after 18 4 months. Adjunct therapy with
sildenafil reversed the deterioration and increased the 6-min walk distance to 346  26 m (p
 0.002, Wilcoxon test) at three months of combined therapy, with a sustained efficacy up
to 12 months (349  32 m, p  0.002). The distribution of New York Heart Association
functional classes (IV/III/II) improved from September 9, 2000, before sildenafil, to January
8, 2003, after nine to 12 months with sildenafil. All hemodynamic variables changed
favorably: pulmonary vascular resistance decreased from 2,494  256 before sildenafil to
1,950  128 dynesscm5m2 after three months of adjunct sildenafil (p  0.036). Two
patients died of severe pneumonia during the period of combined therapy. No further serious
adverse events occurred.
CONCLUSIONS In patients with severe PAH deteriorating despite ongoing prostanoid treatment, long-term
adjunct oral sildenafil improves exercise capacity and pulmonary hemodynamics. A combi-
nation of prostanoids and sildenafil is an appealing concept for future treatment of pulmonary
hypertension. (J Am Coll Cardiol 2003;42:158–64) © 2003 by the American College of
Cardiology Foundation
Continuous infusion of prostacyclin has been shown to be a
life-saving therapy in severe primary pulmonary hyperten-
sion (PPH) (1) and to improve exercise capacity in collagen
vascular disease–associated pulmonary hypertension (2).
There are, however, serious drawbacks with this therapy,
including substantial systemic side effects due to the lack of
pulmonary selectivity of the prostanoid, the need for a
progressive dosage increase, and septic complications of the
intravenous line. To keep the advantageous effects of pros-
tacyclin but leave behind several of these side effects, the
concept of aerosolized iloprost for the treatment of pulmo-
nary arterial hypertension (PAH) was developed (3,4).
Iloprost is a chemically stable prostacyclin analogue (5)
effecting strong pulmonary vasodilation upon inhalation as a
nebulized agent (4,6–9). Several open-label, uncontrolled
studies in severe pulmonary hypertension suggested that
long-term use of aerosolized iloprost (6 to 9 inhalations per
day) results in substantial clinical improvement (4,6,7,10–
12). This notion was just recently corroborated by the
results of a double-blinded, placebo-controlled, multicenter
study: in patients with selected forms of PAH and chronic
thromboembolic pulmonary hypertension, daily inhaled ilo-
prost significantly improved exercise capacity, New York
Heart Association (NYHA) functional class, dyspnea scor-
ing, and event-free survival over a three-month observation
period (13).
To further improve the inhalative therapy while main-
taining preferential vasodilation in the pulmonary circula-
tion, strategies for combination with phosphodiesterase
(PDE) inhibitors were developed. The PDEs represent a
superfamily of enzymes, with PDE-1 through PDE-11
being currently known, that inactivate cyclic adenosine
monophosphate and cyclic guanosine monophosphate
(cGMP), the second messengers of prostacyclin and nitric
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oxide, with different tissue distribution and substrate spec-
ificities (14). Due to stabilization of these second messen-
gers, PDE inhibitors offer to augment and prolong
prostanoid- and nitric oxide–related vascular effects, and the
efficacy of this approach has been proven in several experi-
mental studies (15–18). Interestingly, the major cGMP-
degrading phosphodiesterase, PDE-5, is abundantly ex-
pressed in lung tissue (19). Three recent studies investigated
the short-term effects of orally administered sildenafil, a
selective PDE-5 inhibitor that has been approved for the
treatment of erectile dysfunction in patients with severe
pulmonary hypertension (20–22). Interestingly, this agent,
per se, caused pulmonary vasodilation, with amplification of
the pulmonary vasodilatory effect when combined with
inhaled iloprost, while maintaining pulmonary selectivity.
In the present study, we extended this approach to
long-term treatment with oral sildenafil combined with
inhaled iloprost. Within a study entry period of one year, all
PAH patients receiving long-term inhalative iloprost treat-
ment were regularly surveyed, and those fulfilling predefined
criteria of clinical deterioration were offered oral sildenafil as
adjunct therapy while leaving the iloprost inhalation regi-
men unchanged. Most impressively, all 14 severely ill
pulmonary hypertensive patients selected according to these
criteria displayed marked improvement of their clinical
state, exercise capacity, and hemodynamics over the subse-
quent nine- to 12-month observation period. This is the
first trial demonstrating that a suitable combination of
prostanoid and PDE inhibitor has beneficial long-term
effects in patients with severe pulmonary hypertension.
METHODS
Patients. In 2001, a total number of 73 patients with PAH
were treated with long-term inhaled iloprost in our pulmo-
nary hypertension referral center on an outpatient basis. All
patients had initially been admitted to our center for testing
of pulmonary vasoreactivity and evaluation of therapeutic
options for severe pulmonary hypertension. Diagnostic pro-
cedures that had been performed preceding iloprost treat-
ment and that were repeated according to clinical necessities
included immunologic laboratory analysis, chest X-ray, lung
function testing, carbon dioxide diffusion testing, echocar-
diography, high-resolution computed tomography of the
lung, lung perfusion scintigraphy, and a spiral computed
tomographic scan and/or pulmonary angiography for exclu-
sion of chronic thromboembolism as the underlying reason
for pulmonary hypertension. All patients were offered out-
patient visits every three months for control of therapy,
performance of the unencouraged 6-min walk test, and
assessment of NYHA functional class; more frequent visits
occurred based on clinical necessity. Patients were suggested
to enter the present study when at least two of the following
criteria of deterioration were fulfilled over a three-month
observation period: 1) subjective clinical worsening; 2)
deterioration in 6-min walk distance of more than 20%; 3)
signs of increased right heart load, despite adapted dose
increases of the ongoing iloprost therapy and optimization
of diuretics (e.g., edema refractory to diuretic therapy,
ascites or pleural effusion refractory to diuretic therapy,
increased liver enzymes attributable to venous congestion,
central venous pressure 17 mm Hg or higher); and 4)
syncope.
Within the study entry period in 2001, in total, 18 of the
73 PAH patients receiving long-term inhaled iloprost ther-
apy fulfilled these criteria. Fourteen of these 18 patients
agreed to enter the present study with oral sildenafil as
adjunct therapy to inhaled iloprost. Nine of the 14 patients
suffered from PPH, and five had PAH associated with
collagen vascular disease. The mean age of these patients
was 58  3 years, and the average iloprost inhalation
frequency was 9/day. For assessment of hemodynamics, a
thermodilution pulmonary artery catheter was used to mea-
sure central venous pressure, pulmonary artery pressure,
pulmonary artery wedge pressure, and cardiac output. Pa-
tients received nasal oxygen throughout the entire test
procedure to achieve arterial oxygen saturation 88%.
Measurements were performed after an overnight break of
prostanoid inhalation (pre-iloprost) and 15 min after per-
forming an iloprost inhalation maneuver (post-iloprost), as
described previously (23). When assessing hemodynamics
after the onset of long-term adjunct sildenafil treatment, the
pre-iloprost values were measured 10 h after the last oral
intake of the routine sildenafil dose the night before (25 to
50 mg; see subsequent text).
When fulfilling the study entry criteria, oral treatment
with sildenafil was commenced, while leaving the iloprost
inhalation regimen unchanged during the period of combi-
nation therapy. The sildenafil dosage was slowly increased
over three to four days, allowing final target doses between
25 mg three times per day (9 of 14 patients) and 50 mg three
times per day (5 of 14 patients). Outpatient visits were then
performed every four weeks for control of therapy. After
three months, complete clinical evaluation and catheter
testing were again performed, and clinical evaluation was
repeated after six months and after nine to 12 months.
The study protocol was approved by the Ethics Commit-
tee of the Justus-Liebig-University Giessen, and each pa-
tient gave written, informed consent. Data were evaluated
before initiation of adjunct sildenafil therapy (pre-sildenafil)
and up to 12 months of combined therapy. Moreover, for
the 14 patients entering the study, data were compared with
the initial baseline clinical and catheter evaluation before
starting iloprost therapy and with the data obtained after the
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first three months of iloprost treatment. The mean interval
between the onset of long-term iloprost inhalation therapy
and the onset of adjunct sildenafil therapy due to clinical
deterioration was 18  4 months.
Statistics. All baseline data are given as the means and
SEM. The Wilcoxon signed rank test was used to display
significant differences (with two-sided p value) in the 6-min
walk distance and pulmonary vascular resistance index in
response to co-administration of sildenafil. Hodges-
Lehman point estimates of median differences and exact
95% confidence intervals are presented for the response of
each parameter to the intervention (pre- and post-
intervention values) (StatExact-4 version 4.0.1, Cytel Soft-
ware Corp., Cambridge, Massachusetts).
RESULTS
Baseline exercise capacity and hemodynamics before
starting iloprost therapy. The initial 6-min walk distance
of the patients entering the study was 217  31 m (mean 
SEM) (Fig. 1). According to a standardized clinical evalu-
ation protocol, five patients were classified in NYHA class
III and nine patients in class IV (Fig. 2). Detailed baseline
hemodynamics for all patients are given in Table 1. The
severity of the disease was reflected by a mean pulmonary
artery pressure of 58.4  2.4 mm Hg, a cardiac index of 2.0
 0.2 l/min1m2, a pulmonary vascular resistance index
of 2,312  271 dynesscm5m2, and a central venous
pressure of 8.3  1.5 mm Hg.
Exercise capacity and hemodynamics after the initial
three-month period of iloprost therapy. Over this period,
the 6-min walk distance increased to 305  28 m (Fig. 1).
The majority of patients were then in NYHA functional
class III (Fig. 2). Pre-inhalation hemodynamics, assessed in
the morning after an overnight break of iloprost inhalation,
were largely unchanged but markedly improved in response
to prostanoid inhalation (Table 1, Fig. 3). This improve-
ment included a decrease in pulmonary artery pressure,
pulmonary vascular resistance, and central venous pressure
and an increase in the cardiac index. Heart rate and systemic
arterial pressure were virtually unchanged in response to
iloprost inhalation.
Figure 1. Time course of 6-min walk distance in response to iloprost and sildenafil treatment. Mean and SEM are given for the 6-min walk distance. Data
were obtained at baseline, after three months of inhaled iloprost therapy (Ilo 3 months), after a mean interval of 18  4 months upon clinical deterioration
(Pre-Sil), and after 3, 6, and 9 to 12 months of adjunct sildenafil therapy while leaving the iloprost regimen unchanged (Sil-Ilo). Plus signs with vertical
bars on either side demonstrate significant differences in walk distance (assessed by Wilcoxon test, two-sided p values given) for the impact of adjunct
sildenafil treatment.
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Exercise capacity and hemodynamics before initiation of
adjunct sildenafil therapy. After a mean treatment period
of 18  4 months, worsening was apparent from a substantial
loss of the initial increment in the 6-min walk distance (256
30 m) (Fig. 1). The majority of patients had again switched to
NYHA class IV (Fig. 2). At this time point, the pre-inhalation
pulmonary vascular resistance was increased and the cardiac
index was decreased compared with the initial baseline values,
with a clear beneficial response to the iloprost inhalation (Table
1, Fig. 3).
Figure 2. Distribution of patients (n 14) in New York Heart Association (NYHA) functional classes. The numbers of patients classified in class II (open
bars), III (bars with diagonal lines), or IV (solid bars) are given for the initial pre-intervention baseline, for three months of inhaled iloprost therapy (Ilo
3 months), for a mean interval of 18 4 months when clinical deterioration was noted (Pre-Sil), and for 3, 6, and 9–12 months of adjunct sildenafil therapy
while leaving the iloprost regimen unchanged (Sil-Ilo). Note that one patient died between three and six months and one died at eight months of adjunct
sildenafil therapy (n  13 penultimate and n  12 ultimate column).
Table 1. Hemodynamics at Baseline and in Response to Iloprost and Sildenafil Treatment
HR
(beats/min)
mSAP
(mm Hg)
mPAP
(mm Hg)
CVP
(mm Hg)
CI
(l/min per m2)
PVRI
(dynes·s·cm5m2)
Baseline 80.3  2.5 92.8  3.5 58.4  2.4 8.3  1.5 2.0  0.2 2.312  271
Iloprost at 3 months
Pre-ilo 81.5  2.2 96.3  3.7 58.3  2.4 7.7  1.6 2.0  0.2 2,266  212
Post-ilo 83.5  2.3 89.7  4.0 49.5  3.1 5.5  1.0 2.5  0.2 1,549  214
Pre-sildenafil
Pre-ilo 82.4  2.8 92.5  3.1 58.6  2.1 10.1  1.3 1.8  0.1 2,494  256
Post-ilo 81.1  2.2 89.0  3.3 50.7  3.2 5.7  1.0 2.3  0.1 1,640  212
Sildenafil  iloprost at 3 months
Pre-ilo 80.4  2.5 88.4  3.0 58.6  2.6 5.3  1.2 2.2  0.2 1,950  128
Post-ilo 78.6  2.3 80.6  2.5 47.8  3.2 3.9  1.3 2.6  0.2 1,309  114
Absolute values (mean  SEM) of hemodynamic parameters are given: 1) for the initial pre-intervention baseline; and 2) for later time points, when measurements were
undertaken in the morning after an overnight break of iloprost inhalation (pre-ilo) and subsequent to iloprost inhalation (post-ilo). The latter data pairs were obtained after 3
months of inhaled iloprost therapy (iloprost at 3 months), after a mean interval of 18  4 months on clinical deterioration (pre-sildenafil), and after 3 months of adjunct sildenafil
therapy while leaving the iloprost regimen unchanged (sildenafil  iloprost).
CI  cardiac index; CVP  central venous pressure; HR  heart rate; mPAP  mean pulmonary artery pressure; mSAP  mean systemic arterial pressure; PVRI 
pulmonary vascular resistance index.
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Exercise capacity and hemodynamics after 3, 6, and 9 to
12 months of adjunct sildenafil therapy. In each single
patient, the 6-min walk distance increased upon the onset of
combined therapy. The walking distance increased to 346
26 m (p  0.002 vs. pre-sildenafil [Wilcoxon test]), 338 
32 m (p  0.014), and 349  32 m (p  0.002) after 3, 6
and 9 to 12 months of adjunct sildenafil (Fig. 1). The
Hodges-Lehmann point estimates of median differences
between pre- and post-sildenafil values and exact 95%
confidence intervals (CI) were 86 m (CI 30 to 144), 69 m
(CI 21 to 135), and 87 (CI 22 to 152). Clinical improve-
ment was also reflected by a favorable change in NYHA
class distribution: 2 patients after 3 months (3 patients after
6 months and 3 patients after 9 to 12 months) were
classified in class II; after 3 months 9 patients were classified
in class III (8 patients after 6 months, and 8 patients after 9
to 12 months), and after 3 months 9 patients were classified
in class IV (2 patients after 6 months, and 1 patient after 9
to 12 months) (Fig. 2). Moreover, the pulmonary vascular
resistance index was significantly decreased compared with
the pre-sildenafil values, though being assessed at the nadir
of sildenafil medication (10 h after last intake) (Fig. 3). A
further reduction on inhalation of iloprost was still noted. In
line with these observations, higher pre- and post-iloprost
values of the cardiac index and lower values of central
venous pressure were observed (Table 1).
Adverse events. No sildenafil-related serious adverse
events were reported during the six-month observation
period, including headache, dyspepsia, or unwanted erec-
tions. Ophthalmologic examinations did not reveal abnor-
mal vision. A slight decrease in systemic arterial pressure
was noted (Table 1), but there was no syncope in any patient
during sildenafil treatment, and the patients did not com-
plain of dizziness. One patient, the eldest one included in
the study (73 years old), acquired severe pneumonia after
four months of combined therapy, required mechanical
ventilation, and died of pneumonia-associated septic multi-
organ failure. Another patient with pulmonary hypertension
Figure 3. Time course of pulmonary vascular resistance index (PVRI) in response to iloprost and sildenafil treatment. Values for PVRI are presented as
the mean and SEM. Open squares represent pre-iloprost values, assessed in the morning after an overnight break of prostanoid inhalation. Closed squares
represent PVRI values subsequent to iloprost inhalation. Data pairs (pre- and post-inhalation) were obtained after three months of inhaled iloprost therapy
(Ilo 3 months), after a mean interval of 18 4 months on clinical deterioration (Pre-Sil), and after another three months of adjunct sildenafil therapy while
leaving the iloprost regimen unchanged (Sil-Ilo). Plus signs with vertical bars on either side demonstrate significant differences (assessed by Wilcoxon test,
two-sided p values given) for the impact of adjunct sildenafil treatment.
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associated with CREST (calcinosis cutis, Raynaud’s phe-
nomenon, esophageal dysfunction, sclerodactyly, and telan-
giectasia) syndrome died after eight months of combination
therapy, also due to severe pneumonia and secondary organ
failure in a peripheral hospital. No other deaths occurred,
and no patient had to be hospitalized due to clinical
deterioration.
DISCUSSION
The patients entering this study had severe PAH, as obvious
from the predominance of NYHA functional class IV, the
low 6-min walk distance, and the high pulmonary vascular
resistance, along with low cardiac indexes before starting
iloprost treatment. Compared with the available multicenter
trials in this field, each of these variables reflected a more
serious state of disease; the baseline mean 6-min walk
distances were 315, 326, 362, 330, and 332 m in the
intravenous prostacyclin (1), subcutaneous teproprostinil
(24), oral beraprost (25), oral bosentan (26), and inhaled
iloprost (13) studies, compared with 217 m in the present
investigation. Impressive improvement of exercise capacity
and NYHA class was noted at the onset of inhaled iloprost
treatment, despite the lack of improved baseline hemody-
namics of the pulmonary circulation. This finding is well in
line with the marked increase in walking distance noted in
PAH patients under iloprost therapy in a recent multicenter
trial (13). Notably, this improvement was not due to a
specific “responder” state of the patients currently investi-
gated, as none of them fulfilled nitric oxide responder
criteria (27) assessed before the onset of iloprost therapy.
Despite this beneficial initial response to treatment,
deterioration of the 6-min walk distance, NYHA class, and
hemodynamics was noted after a mean treatment period of
18 4 months. In none of these cases was this deterioration
explained by intervening events, such as interruption of
therapy or lung infection, but apparently reflected progres-
sion of the underlying disease. Similar observations have
been made in PPH patients receiving long-term prostacy-
clin infusion (28–30), and the percentage of patients dete-
riorating and succumbing under this regimen was recently
reported to be even higher in collagen vascular disease–
associated PAH than in PPH (30–32). Accordingly, pul-
monary hypertensive patients who are failing while receiving
long-term prostanoid treatment are commonly regarded as
urgent lung-transplant candidates (33,34).
Taking this deterioration as a starting point of the present
study, adjunct treatment with sildenafil not only achieved
stabilization but also resulted in a marked and persistent
improvement in 6-min walk distance in each single patient
(up to 1-year observation period under combination thera-
py). Concomitantly, NYHA functional class improved by
one class in most patients, pulmonary vascular resistance
(assessed in the morning after a 10-h sildenafil pause)
decreased to the lowest values ever measured in these
patients, and the other hemodynamic variables changed
accordingly. Although the study was non-controlled, the
consistency and high statistical significance of the changes
reliably indicate a strong beneficial effect of the combined
therapy. Of interest, even given the marked reduction of
baseline pulmonary vascular resistance after three months of
combined treatment, the iloprost inhalation maneuver still
caused a substantial further reduction of resistance. This
finding corroborates studies with vasodilator testing show-
ing additive lung vasorelaxant capacity of oral sildenafil and
inhaled iloprost (20,21).
Although a high inhalation frequency might be cumber-
some, the vast majority of patients currently treated with
this approach are not significantly impaired by this proce-
dure. The duration of each inhalation could be reduced to 4
min, due to improvements of nebulizer techniques. Still,
one advantage of the combination therapy could be to
reduce the frequency of inhalations by prolonging the
duration of the vasodilation subsequent to each inhalation.
However, in this particular study population of severely
impaired patients, the primary objective was to maximize
the therapeutic effect.
According to the concept of selective vasodilation, only a
minor decrease in systemic blood pressure was noted in
response to the combined therapy in PAH patients. More-
over, there were no serious adverse events under this
regimen, including ophthalmologic controls undertaken in
view of a putative retinal effect of the PDE-5 inhibitor. In
view of the severity of disease of the group of patients
included, the present death rate was impressively low (32).
The two deaths were both associated with severe pneumo-
nia, without preceding right heart failure. Pneumonia in this
severely compromised patient collective is often observed to
be life-threatening. Moreover, there was no evidence of an
increased incidence of respiratory tract infections associated
with the treatment in the recent randomized, controlled trial
with inhaled iloprost (13).
Conclusions. The present study provides strong evidence
that patients who are failing while receiving inhaled iloprost
may be rescued by adjunct treatment with oral sildenafil.
This is most remarkable as pulmonary hypertensive patients
deteriorating despite long-term prostanoid therapy are com-
monly regarded as urgent candidates for lung transplanta-
tion. This is the first report of successful use of combined
vasodilator therapy in a series of pulmonary hypertensive
patients. Despite the limitations of a non-controlled study,
the present investigation, due to the profound and lasting
improvements observed, strongly suggests that co-
administration of prostanoid and PDE-5 inhibitor opens a
new perspectives for the treatment of pulmonary hyperten-
sion and warrants controlled clinical trials for definite proof.
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